anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Reducing ultra-processed foods (UPF) improves diet quality and may curb energy consumption. This study aimed to compare an intervention based on the reduction of UPF, according to the Dietary Guideline for the Brazilian Population (DGBP), with and without advice on energy intake. A parallel and randomised controlled trial was carried out with children with obesity from 7 to 12 years old. Both control (CG) and intervention groups (IG) participated monthly in 6 standardised educational activities based on the 10 steps of the DGBP. An individualised food plan was also provided to the IG. The rate of change for body mass index (BMI), waist circumference, body weight, and UPF consumption were investigated based on mixed-effect models. At the end of the study, the BMI declined in the IG (Δ = -0.27 kg/m2) compared to the CG (Δ = + 0.53 kg/m2) (p = .0002). Both groups showed a decline in grams of UPF until the fourth month and a gradual increase in the following months. Combining the qualitative approach of the DGBP with counselling on energy restriction through the diet plan proved to be effective in reducing childhood obesity. Clinical Trial Registration: This trial is registered at the Brazilian Registry of Clinical Trials (REBEC), under the RBR-3st5sn registry, available at http://www.ensaiosclinicos.gov.br/rg/RBR-3st5sn/. The datasets generated by the current study are not publicly available but are available from the corresponding author on reasonable request.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic excellent in water resistance and stability, good in extensivity and having a refreshing touch by compounding an alkyl- modified carboxylvinylpolymer exhibiting water repellency and an organic silicone resin having a specific structure. SOLUTION: A skin cosmetic contains an alkyl-modified carboxyvinyl polymer and one or more kinds of organic silicone resins containing structural units of the formula (R<1> is a 1-6C hydrocarbon; n is 1.0-1.8) and having an average mol. wt. of 1500-10000. The organic silicone resin is preferably added in an amount of 0.05-50wt.% based on the whole amount of the skin cosmetic. The alkyl-modified carboxyvinyl polymer is preferably added in an amount of 0.01-10wt.% based on the whole amount of the skin cosmetic. The cosmetic can hold a skin roughnessimproving effect over a long time and further prevent its adhesion to contact articles.
Patients receive neoadjuvant CCRT and neoadjuvant CTx. Radical cystectomy is performed depending on pathologic response. The patients showing clinical complete response after neoadjuvant CCRT and initially stage T2N0M0 are not treated with neoadjuvant chemotherapy.
Staphylococcus aureus is a notorious pathogen predominantly involved in skin and soft tissue infections, exhibiting a distinct innate sex bias. This study explores the influence of testosterone on the virulence of S. aureus and elucidates its underlying mechanisms. Utilizing a skin abscess model in intact and castrated male mice, we assessed the effects of testosterone on S. aureus pathogenicity. Compared to controls, castrated mice showed significantly reduced abscess sizes and decreased bacterial loads, highlighting the role of testosterone in modulating the severity of S. aureus infections. In vitro experiments revealed that testosterone enhances the hemolytic activity, cytotoxicity, and oxidative stress resistance of S. aureus. Real-time quantitative PCR analysis showed a significant upregulation of the genes encoding α-hemolysin (hla) and phenol-soluble modulin (psmα). Importantly, testosterone treatment significantly enhanced the expression of the accessory gene regulator (Agr) quorum-sensing system components (agrC, agrA, agrB, agrD), while the SaeRS system (saeR, saeS, and sbi) exhibited only slight changes. Gene knockout experiments revealed that deletion of agrC, rather than saeRS and agrBD, abolishes the testosterone-induced enhancement of hemolysis and gene expression, underscoring the key role of AgrC. Molecular docking simulations indicated a direct interaction between testosterone and AgrC protein, with a strong binding affinity at the active site residue SER201. This study provides new insights into the mechanistic basis of how testosterone enhances the pathogenicity of S. aureus, potentially contributing to increased male susceptibility to S. aureus infections and offering a targeted approach for therapeutic interventions.
The purpose of this study is to examine the efficacy of exercise and wellness/support interventions for preventing postpartum depression. Specifically, 450 sedentary postpartum women (2-6 weeks postpartum) with a history of depression prior to pregnancy will be randomized to one of three groups each lasting six months: (1) telephone-based exercise intervention; (2) telephone-based wellness/support intervention; or (3) usual care. Participants will also complete a follow-up assessment session at 9 months. Participants will be recruited via online, email, and print advertisements. The investigators will obtain healthcare provider consent for each participant prior to randomization. The exercise intervention will consist of a theory-based telephone intervention shown to increase exercise among postpartum women in a previous study (Lewis et al., 2011). The wellness/support condition will be on the same schedule as the exercise intervention and will address several topics related to wellness. The usual care condition will receive their choice of the exercise or wellness/support condition upon completion of their final assessment. The primary dependent variable will be depression as measured by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Edinburgh Postnatal Depression Scale (EPDS). Exercise adherence will be assessed using the 7-Day Physical Activity Recall Interview and the ActiGraph (i.e., an accelerometer, an objective measure of exercise).
In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
BACKGROUND: The incidence of oral squamous cell carcinoma (OSCC) is increasing, and more effective treatment protocols must rapidly be developed to prevent the death of patients and ensure favorable outcomes. CircRNAs are a unique class of noncoding ribonucleic acid (RNA) molecules unaffected by RNA exonucleases. CircRNAs have more stable expression than linear RNAs and are not readily degraded; therefore, they are the newest focus of RNA research. Here, we analyze the mechanism of hsa_circ_0004771 (circ_0004771) in OSCC to provide a clinical reference.
METHODS: Circ_0004771 expression was measured in peripheral blood, cancerous tissues and adjacent tissues of OSCC patients. Patients were followed up for 3 years. The diagnostic value of circ_0004771 for OSCC occurrence, prognosis, recurrence and survival was analyzed with receiver operating characteristic (ROC) curves. OSCC cells were lentivirally transduced with a circ_0004771-silencing or an empty vector to evaluate alterations in cell growth, invasion, and apoptosis. Apoptosis-related and epithelial-mesenchymal transition (EMT)-related protein expression was quantified. BALB/c nude mice were used for tumorigenesis experiments to evaluate tumor growth in vivo after silencing circ_0004771.
RESULTS: Circ_0004771 expression was higher in peripheral blood and cancerous tissue of OSCC patients than in control peripheral blood and paracancerous tissue, respectively, exhibiting excellent predictive value for OSCC occurrence, prognosis, recurrence and survival. Silencing circ_0004771 decreased the growth, invasiveness, and EMT capacity and increased the apoptosis of OCC cells. In mice implanted with OSCC cells transduced with the circ_0004771-silencing lentiviral vector, the tumor growth capacity was obviously decreased.
CONCLUSION: Silencing circ_0004771 inhibits the malignant growth of OSCC.
PURPOSE:To obtain a composition for external use in the scalp capable of manifesting ultrahigh suppressing effects on dandruff and pruritus and further excellent in persistence of the effects by using an antimicrobial agent used for the purpose of preventing the dandruff and pruritus with a keratinization improving agent. CONSTITUTION:This composition for external use in the scalp is obtained by using an antimicrobial agent which is a preventing agent for dandruff and pruritus and a keratinization improving agent comprising an amine derivative of formula I [R<1> is a 4-40C straight-chain, branched chain or cyclic saturated or unsaturated hydrocarbon; R<2> to R<6> are each H or a 1-10C hydrocarbon (which can be substituted with OH)] or its acid addition salt in combination. An antimicrobial agent selected from a polyvalent metallic salt of 2- mercaptopyridine N-oxide, a 1-hydroxy-2-pyrrolidone derivative of formula II (R<7> is an alkyl, an alkenyl, a cycloalkyl, etc.; R<8> is H, an alkyl, an alkenyl, etc.; X<-> is an organic salt group, a cation, etc.), 2,2'-dithio-bis-(pyridine N-oxide) of formula III and a benzalkonium salt of formula IV (R<13> is a hydrocarbon; Y<-> is an anion residue such as a phosphoric ester) is especially preferred as the antimicrobial agent.
INTRODUCTION: Lumbar facet cysts represent a potential source of nerve root compression in elderly patients. Isolated decompression without fusion has proven to be a reasonable treatment option in properly indicated patients. However, the risk of lumbar fusion after isolated decompression and facet cyst excision has yet to be elucidated.
METHODS: The PearlDiver database was reviewed for patients undergoing isolated laminectomy for lumbar facet cyst from January 2015 to December 2018 using Current Procedural Terminology coding. Patients undergoing concomitant fusion or additional decompression, as well as those diagnosed with preexisting spondylolisthesis or without a minimum of 5-year follow-up, were excluded. Rates of subsequent lumbar fusion and potential risk factors for subsequent fusion were identified. Statistical analysis included descriptive statistics, chi square test, and multivariate logistic regression. Results were considered significant at P < 0.05.
RESULTS: In total, 10,707 patients were ultimately included for analysis. At 5-year follow-up, 727 (6.79%) of patients underwent subsequent lumbar fusion after initial isolated decompression. Of these, 301 (2.81% of total patients, 41.4% of fusion patients) underwent fusion within the first year after decompression. Multivariate analysis identified chronic kidney disease, hypertension, and osteoarthritis as risk factors for requiring subsequent lumbar fusion at 5 years following the index decompression procedure ( P < 0.033; all).
CONCLUSION: Patients undergoing isolated decompression for lumbar facet cysts undergo subsequent lumbar fusion at a 5-year rate of 6.79%. Risk factors for subsequent decompression include chronic kidney disease, hypertension, and osteoarthritis. This study will assist spine surgeons in appropriately counseling patients on expected postoperative course and potential risks of isolated decompression.
The invention relates to a human health information detection and early warning system and method. The detection and early warning system at least comprises: the system comprises a first sensor, a second sensor, a processor and an intelligent terminal. The first sensor and the second sensor are configured to acquire the same type of physiological data at different locations of the patient. The processor is configured to determine a reference value for physiological data of the patient based on the physiological data acquired by the first sensor and the second sensor; and under the condition that the reference value reaches the threshold value, the processor can generate early warning information and send the early warning information to an intelligent terminal configured by medical staff. The physiological data includes at least one of arterial stiffness, vascular age, blood oxygen saturation, heart rate, and blood pressure. The processor can set a threshold according to personal data of the patient and pre-stored historical case data, and correct the reference value of the physiological data of the patient by utilizing the personal data of the patient, thereby providing a practical and reliable basis for diagnosing the illness state of the patient and determining the relevant treatment scheme.
PROBLEM TO BE SOLVED: To obtain a deodorant compsn. having an enhanced deodorizing effect and less liable to affect the earthly environm,ent by incorporating a phenolic compd. and enzyme oxidizing the phenolic compd. SOLUTION: At least a phenolic compd., i.e., a compd. having one or two phenolic hydroxyl groups, e.g. catechol or 4-methylcatechol and enzyme oxidizing the phenolic compd., e.g. polyphenol oxidase are incorporated to obtain the objective deodorant compsn. The enzyme means enzyme having action to oxidize the phenolic compd. to quinone by adding phenolic hydroxyl groups as well as enzyme having action to oxidize the phenolic compd. to a compd. having a quinone structure. An enzyme-contg. material or compsn. may be used in place of the enzyme oxidizing the phenolic compd. if it has the oxidizing action.
1,153,927. Medicinal compositions. W. HORRMANN. 22 Aug., 1967 [25 Aug., 1966], No. 38700/67. Heading A5B. A medicinal composition for the treatment of diseases of the retina particularly macular degeneration comprises dimethylmaleic anhydride and/or a dimethylmaleic and/or dimethyl fumaric acid compound having the following general formula: wherein each of R and R 1 , which may be the same or different, represents a hydrogen atom, a pharmacologically acceptable cation or a pharmacologically acceptable group corresponding to a mono-or polyhydric alcohol from which the or one hydroxyl group has been removed; in admixture with a pharmacologically acceptable carrier or diluent therefor. Examples of suitable cations are inorganic cations such as Na, Ca and ammonium ions and organic cations such as are produced by anion exchange resins of the primary, secondary and tertiary amine type e.g. Amberlite (Trade Mark), styrene and phenolic resins and polycondensates of an aromatic and/or aliphatic amine with an aldehyde or ketone. The alcohol may be be ethanol, glycol, glycerol, 1,2-propylene glycol, mannitol or sorbitol. The compositions may be administered orally, parenterally or topically and may be in the form of tablets, diffusion pellets, suppositories, syrups, aqueous solutions or capsules containing binding agents, expanding agents, delaying action agents (e.g. lipoids, fats, waxes and salts of fatty acids), tasteimproving agents (e.g. sugar and lactose), antacids (such as magnesium oxide, hydrated magnesium trisilicate and aluminium hydroxide), natural and synthetic gums and mucouslike materials (such as methylcellulose, carboxycellulose and dextrans).
The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contacted immediately prior to administration, or can be contacted in culture for a specified period of time prior to administration. In the method of the invention, an effective amount of the cell/microparticle composition is administered to a patient in need thereof by injection to a treatment site of the patient to provide a therapeutic effect in the patient. The therapeutic effect can be, for example, the formation of new tissue at the treatment site, or the production and secretion of a biologically active secretory molecule at the treatment site. The composition comprising live cells and biocompatible, biodegradable polymer microparticles can be use in a method of generating new tissue in vitro. The method comprises placing the composition in a cell culture chamber under conditions wherein a coherent mass of tissue is formed. In a particular embodiment, the culture chamber is in a specified shape which results in the generation tissue having said shape.
The precise mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit transmethylation of methyl groups of methionine into t‑RNA. The absence of functional t‑RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA. Hydrogen peroxide, formed during the auto‑oxidation of the drug, may attack protein sulfhydryl groups contained in residual protein which is tightly bound to DNA.

Procarbazine is metabolized primarily in the liver and kidneys. The drug appears to be auto-oxidized to the azo derivative with the release of hydrogen peroxide. The azo derivative isomerizes to the hydrazone, and following hydrolysis splits into a benzylaldehyde derivative and methylhydrazine. The methylhydrazine is further degraded to CO2 and CH4 and possibly hydrazine, whereas the aldehyde is oxidized to N-isopropylterephthalamic acid, which is excreted in the urine.

Procarbazine is rapidly and completely absorbed. Following oral administration of 30 mg of 14C-labeled procarbazine, maximum peak plasma radioactive concentrations were reached within 60 minutes.

After intravenous injection, the plasma half-life of procarbazine is approximately 10 minutes. Approximately 70% of the radioactivity is excreted in the urine as N-isopropylterephthalamic acid within 24 hours following both oral and intravenous administration of 14C-labeled procarbazine.

Procarbazine crosses the blood-brain barrier and rapidly equilibrates between plasma and cerebrospinal fluid after oral administration.
Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
PCT No. PCT/EP93/00183 Sec. 371 Date Sep. 22, 1994 Sec. 102(e) Date Sep. 22, 1994 PCT Filed Jan. 27, 1993 PCT Pub. No. WO93/15197 PCT Pub. Date Aug. 5, 1993The present invention is directed towards a method of producing a DNA sequence encoding human osteogenic protein, OP-1, using recombinant DNA techniques. The DNA sequence encoding OP-1 is utilized in the preparation of recombinant baculovirus, which is then used to infect cells from Spodoptera frugiperda. The present invention is further drawn to the production of physiologically active OP-1 protein by culturing the infected insect cells and to recombinant baculovirus containing DNA encoding human OP-1 as well as insect cells infected with the recombinant baculovirus. The recombinant OP-1 produced by the present invention may be used to produce pharmaceutical compositions useful in the treatment of bone diseases, orthopedic diseases, bone defects, and trauma.
Ulcerative colitis (UC) is a chronic disorder of the large intestine with inflammation and ulceration. The incidence and prevalence of UC have been rapidly increasing worldwide, but its etiology remains unknown. In patients with UC, the accumulation of eosinophils in the large intestinal mucosa is associated with increased disease activity. However, the molecular mechanism underlying the promotion of intestinal eosinophilia in patients with UC remains poorly understood. Here, we show that uridine diphosphate (UDP)-glucose mediates the eosinophil-dependent promotion of colonic inflammation via the purinergic receptor P2Y14. The expression of P2RY14 mRNA was upregulated in the large intestinal mucosa of patients with UC. The P2Y14 receptor ligand UDP-glucose was increased in the large intestinal tissue of mice administered dextran sodium sulfate (DSS). In addition, P2ry14 deficiency and P2Y14 receptor blockade mitigated DSS-induced colitis. Among the large intestinal immune cells and epithelial cells, eosinophils highly expressed P2ry14 mRNA. P2ry14-/- mice transplanted with wild-type bone marrow eosinophils developed more severe DSS-induced colitis compared with P2ry14-/- mice that received P2ry14-deficient eosinophils. UDP-glucose prolonged the lifespan of eosinophils and promoted gene transcription in the cells through P2Y14 receptor-mediated activation of ERK1/2 signaling. Thus, the UDP-glucose/P2Y14 receptor axis aggravates large intestinal inflammation by accelerating the accumulation and activation of eosinophils.
This is a Phase II, multicenter, single-arm, open label study of AB-106 in the Chinese patients with advanced NSCLC harboring ROS1 fusion gene.The study will be divided into two stages. First stage (Stage I) is to determine the clinical optimal dose of AB-106, which will be evaluated at two dose levels (400 mg QD and 600mg QD), and the safety, tolerability and pharmacokinetics of AB-106 will be evaluated at the same time; Second stage (Stage II) is to evaluate the efficacy and safety of AB-106 at the clinical optimal dose determined from Stage I. It is expected that 6 patients with advanced NSCLC harboring ROS1 fusion will be enrolled in the first stage. About 167 patients with ROS1 fusion will be enrolled in the second stage and divided into two treatment cohorts (Cohort A \& Cohort B). It is planned to enroll about 106 ROS1-TKI treatment naïve patients in Cohort A and about 67 crizotinib pre-treated patients in Cohort B. AB-106 will be administered 600mg once daily in 21-day cycles. Patients will continue with the study treatment until progression of disease as determined by the investigator. The tumor response evaluation will be conducted in every 6 weeks in the first 8 cycles, and then every 12 weeks until progression of disease as determined by the investigator. The long-term survival follow up will be conducted every 12 weeks.
The present invention relates to multispecific, in particular bispecific, antibodies and fragments and variants thereof that specifically bind the T cell receptor of gamma delta T cells, and one other antigen. More specifically, the present invention provides at least two new classes of bispecific antibodies: bispecific T-cell engagers that bind the variable delta 1 (V?1) chain of a ?? T cell receptor (TCR) and a cancer antigen or cancer-associated antigen, and bispecific dual immunomodulators (DIs) that bind the variable delta 1 (V?1) chain of a ?? T cell receptor (TCR) and an immunomodulatory antigen.
Maternal hypercholesterolemia (MHC) during pregnancy is associated with the risk of developing aortic lesions in fetuses. There is also a possibility of faster progression of atherosclerosis in offspring born to hypercholesterolemic mothers (HCM) during their adulthood. We investigated whether elevated maternal cholesterol levels during pregnancy influence the lipid levels in offspring. We analyzed the lipid profile of mothers during the three trimesters, cord blood (CB) at birth, and neonatal blood (NB) on Day 2 postpartum in the offspring. Cholesterol levels of HCM significantly increased throughout gestation when compared to normocholesterolemic mothers (NCM). CB lipid levels of newborns of HCM were similar to the newborns of NCM. While NB of offspring of HCM had elevated levels of triglycerides (TG) (p < 0.01) and very low-density lipoprotein (VLDL) (p < 0.01) when compared to the offspring of NCM. MHC also resulted in low newborn birthweight (p < 0.05) and low placental efficiency (ratio of newborn birth weight to placental weight) (p < 0.01) but no change was observed in umbilical cord length or placental weight. Immunohistochemical analysis revealed no significant changes in the protein expression of genes involved in TG metabolisms such as LDLR, VLDLR, CETP, and PPARG. We report that MHC in mothers decreases placental efficiency and newborn birthweight while increasing lipid levels in neonates on the second postpartum day. Given that TG levels modulate the circulating Low-Density lipoproteins, the increase in these levels in neonates gains importance. Whether these consistently high levels cause atherosclerosis in early adulthood warrants further investigation.